Details for Patent: 7,572,920
✉ Email this page to a colleague
Which drugs does patent 7,572,920 protect, and when does it expire?
Patent 7,572,920 protects EDARBI and EDARBYCLOR and is included in two NDAs.
This patent has sixty-eight patent family members in thirty-two countries.
Summary for Patent: 7,572,920
Title: | Benzimidazole derivative and use as a II receptor antagonist |
Abstract: | The present invention relates to a compound represented by the formula (I) ##STR00001## wherein R.sup.1 is a group represented by the formula ##STR00002## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each independently a hydrogen atom or a C.sub.1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic diseases such as diabetes and the like. |
Inventor(s): | Kuroita; Takanobu (Katano, JP), Sakamoto; Hiroki (Amagasaki, JP), Ojima; Mami (Amagasaki, JP) |
Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
Application Number: | 11/466,633 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,572,920 |
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,572,920
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF HYPERTENSION | ⤷ Try a Trial | |||
Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-002 | Feb 25, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF HYPERTENSION | ⤷ Try a Trial | |||
Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-001 | Dec 20, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF HYPERTENSION | ⤷ Try a Trial | |||
Azurity | EDARBYCLOR | azilsartan kamedoxomil; chlorthalidone | TABLET;ORAL | 202331-002 | Dec 20, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF HYPERTENSION | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,572,920
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2004-048928 | Feb 25, 2004 |
International Family Members for US Patent 7,572,920
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 047972 | ⤷ Try a Trial | |||
Argentina | 094588 | ⤷ Try a Trial | |||
Austria | E370136 | ⤷ Try a Trial | |||
Austria | E440095 | ⤷ Try a Trial | |||
Australia | 2005214271 | ⤷ Try a Trial | |||
Brazil | 122012009489 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |